Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of add-on Eptinezumab Treatment to Brief Educational Intervention for the Preventive Treatment of Migraine in Patients With Dual Diagnosis of Migraine and Medication Overuse Headache

NCT05452239 is registered in ClinicalTrials.gov with H. Lundbeck A/S as lead sponsor.

NCT NCT05452239
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05452239 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Interventional, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of add-on Eptinezumab Treatment to Brief Educational Intervention for the Preventive Treatment of Migraine in Patients With Dual Diagnosis of Migraine and Medication Overuse Headache
Lead sponsor
H. Lundbeck A/S
Phase
Phase 4
Overall status
Completed
Start date
July 1, 2022
Completion date
March 13, 2025
Enrollment
608 (actual)
Sites
76

Conditions

As the registry lists them; a condition with its own page is linked.

medication overuse headache, migraine